Understanding inherited genetic factors that lead to blood cancers.
Official title: Selective pressures from inherited variation impacting myeloproliferative neoplasm initiation
Funded at Boston Children's Hospital · NIH-10867306 · Data updated 2026-11-12
This study is looking at how inherited genes might play a role in the development of blood cancers called myeloproliferative neoplasms, using mice to understand how these genes affect blood stem cells, which could help patients learn more about their own genetic risks and ways to prevent these conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston Children's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | July 1, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $482,599 |
| NIH project number | 5R01CA265726-03 |
| Project ID | NIH-10867306 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with a family history of myeloproliferative neoplasms or those who have been diagnosed with related blood disorders.
✕Less likely to help
Patients without any genetic predisposition to blood cancers or those with unrelated health conditions may not benefit from this research.
What this research studies
This research investigates how inherited genetic variations can influence the development of myeloproliferative neoplasms (MPNs), a type of blood cancer. By utilizing advanced mouse models and genome editing techniques, the study aims to uncover the mechanisms through which these inherited factors affect blood stem cells and contribute to cancer initiation. The research will also explore the role of specific genetic mutations, such as those in the CHEK2 gene, in promoting these diseases. Patients may gain insights into their genetic risks and potential preventive measures.
Why it matters
Potential benefit: If successful, this research could lead to better understanding and potentially new strategies for preventing or treating myeloproliferative neoplasms.
How similar studies have gone: Previous research has shown promising results in understanding genetic factors in blood cancers, indicating that this approach has potential for success.
Where this research is happening
-
Boston Children's Hospital
Boston, United States Active
Researchers
- Principal investigator: Sankaran, Vijay Ganesh — Boston Children's Hospital
- Study coordinator: Sankaran, Vijay Ganesh
Related research
Other NIH-funded projects on the same topics.
-
Complement and clotting in JAK2V617F myeloproliferative neoplasms
A short, patient-friendly study will look at how a specific mutation in blood cells may trigger the body’s complement system to cause clots in people with myeloproliferative neoplasms.
-
Endothelial contribution to blood-clotting in myeloproliferative neoplasms
This project explores how the lining of blood vessels may drive dangerous clots in people with myeloproliferative neoplasms (MPNs).
-
Hypoxia-inducible factors and neutrophil diversity in blood clotting in myeloproliferative neoplasms
A physician-scientist is training over five years to uncover how low-oxygen signals and diverse neutrophils drive dangerous clots in people with myeloproliferative neoplasms, with the goal of finding new treatment targets.
-
Inherited genetic risks shaping myeloid cancer initiation
A research project at Boston Children’s Hospital is exploring how inherited genetic differences may push blood stem cells toward the start of myeloproliferative neoplasms, with potential implications for earlier detection and prevention.
-
Understanding why some myeloproliferative neoplasm patients resist interferon therapy
Researchers are studying why interferon-alpha works for some blood cancer patients but not others, by looking closely at stem cells from CALR-mutated myeloproliferative neoplasms.
-
Genetic and epigenetic factors shaping response in advanced myeloproliferative neoplasms
This grant looks at how genetic and epigenetic differences influence how patients with advanced myeloproliferative neoplasms respond to therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.